| EDITORIAL |
|
| Year : 2021 | Volume
: 2
| Issue : 3 | Page : 51-57 |
|
|
COVID-19 in India: Current status-prevalence, research area, public health, and primary care
Sweety Sharma
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
Correspondence Address:
Sweety Sharma
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jphpc.jphpc_10_21
|
|
|
COVID-19 remains a serious global public health emergency. As of June 18, 2021, there had been 177,108,695 confirmed cases of COVID-19 worldwide, with 3,840,223 deaths. India is currently experiencing the world's worst outbreak, with the new emerging cases. This pandemic has a negative impact on India's public health, primary care, economic activity, and research. There are no proven treatments, and medicines have only been approved for emergency use or as an off-label drug. The growing number of COVID-19 cases causes a shortage of health-care resources such as medicines, testing, hospital beds, oxygen support, ventilators, and so on. The abrupt change in scenario has exacerbated mental health issues. Several clinical trials are underway, and many Indian companies are expected to begin supplying vaccine doses in July, with the hope that the crisis will be under control by the end of the year. This review focuses on the current state of COVID-19 in India in terms of research, public health, primary care, and prevalence.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
